[Skip to the reading](/references#reading) [Peptide Therapy News](/) [Regulatory](/regulatory) [Research](/research) [Archive](/#event-index) [About](/about) Source review through 27 October 2026 · Event dates appear with reports [Home](/) / References # The documents behind the dates The original notices, labels and papers, with a few words on what each tells you. ## Reading the records Peptide Therapy News links to the records behind its reports. This page collects them, with a note on what each explains. The links open the original page or PDF, so you can check the details in context. The publication’s source-review cutoff is 27 October 2026. Dates below identify the announcement, document or source update. An old announcement can explain a past decision without answering what happened later. ## The source desk ### [Step 3: Clinical Research](https://www.fda.gov/patients/drug-development-process/step-3-clinical-research) FDA · checked 27 October 2026 Explains what phase 2 testing can tell researchers, and why more testing follows. ### [National supply and the rules for compounded copies](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) FDA · updates through 1 April 2026 Tracks the shortage decisions and grace periods for compounded copies, medicines prepared outside approved finished-product manufacturing. ### [FDA’s two-table account of peptide nominations](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) FDA · snapshot current as of 22 April 2026 Shows Category 2 and withdrawn requests in separate tables. Withdrawal does not mean safety clearance. ### [FDA’s safety concerns about unapproved medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) FDA · checked 27 October 2026 Explains why compounded medicines are not FDA-approved and why retatrutide cannot be compounded under federal law. ### [American Diabetes Association highlights retatrutide phase 2 findings](https://diabetes.org/sites/default/files/2023-10/ada_sci_sessions_2023_news_release_retatrutide_0.pdf) American Diabetes Association · 26 June 2023 · PDF Announces two mid-stage retatrutide studies: one in adults with type 2 diabetes, one in adults without it. ### [Retatrutide obesity trial: the original paper](https://pubmed.ncbi.nlm.nih.gov/37366315/) New England Journal of Medicine · 2023 Reports weight loss and side effects, including stomach problems and a faster heartbeat, in adults without type 2 diabetes. ### [Retatrutide diabetes trial: the original paper](https://pubmed.ncbi.nlm.nih.gov/37385280/) The Lancet · 2023 Reports blood-sugar and weight findings in adults with type 2 diabetes. This was a different study from the obesity trial. ### [The March 2024 semaglutide cardiovascular decision](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or) FDA · 8 March 2024 Sets out the heart-risk approval for semaglutide, sold as Wegovy, and the adults it covers. ### [Wegovy (semaglutide) prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) National Library of Medicine, DailyMed · checked 27 October 2026 Gives semaglutide’s warnings and the trial evidence behind the heart-risk approval. ### [Drug reverses signs of liver disease in people living with HIV](https://www.nih.gov/news-events/news-releases/drug-reverses-signs-liver-disease-people-living-hiv) National Institutes of Health · 15 October 2019 Announces the year-long tesamorelin study that found lower liver fat in adults living with HIV. ### [Effects of tesamorelin on non-alcoholic fatty liver disease in HIV](https://pubmed.ncbi.nlm.nih.gov/31611038/) The Lancet HIV · 2019 Reports the liver-fat findings in adults with HIV and fatty liver disease. ### [Original Egrifta (tesamorelin) approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022505s000ltr.pdf) FDA · 10 November 2010 · PDF Records tesamorelin’s original approval for excess abdominal fat in HIV-associated lipodystrophy, a change in body-fat distribution. ### [Egrifta WR (tesamorelin) supplement approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022505Orig1s020ltr.pdf) FDA · 25 March 2025 · PDF Approves a new tesamorelin formulation and multiple-dose presentation. It is not a general weight-loss approval. ### [Egrifta WR (tesamorelin) prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75) National Library of Medicine, DailyMed · checked 27 October 2026 Specifies adults, rules out a general weight-loss use, and explains warnings about blood sugar, fluid retention and raised growth-factor levels. ## On this page - [Reading the records](/references#using-records) - [The source desk](/references#source-list) Source review 27 October 2026 [Open the source desk](/references) [Follow the event dates](/#event-index) Peptide Therapy News is a guide for reading the record, not a clinic, pharmacy or seller. © 2026 Peptide Therapy News [References](/references) [About](/about) [Contact](/contact) [Event index](/#event-index)